Article

ICON to Acquire PRA Health Sciences

ICON PLC has agreed to acquire PRA Health Sciences Inc. PRAH, 18.41% in a cash and stock deal valued at about $12 billion. Under the terms of the deal. Icon will pay $80 per share in cash plus 0.4125 shares of Icon stock for a roughly 30% premium over PRA's closing price Tuesday.

The deal is expected to close in the third quarter. The combined company will be headquartered in Dublin and continue to be led by CEO Steve Cutler, and CFO Brendan Brennan.

For more information, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
© Pixel-Shot - © Pixel-Shot - stock.adobe.com
August 5th 2025

Roche Reports Five-Year Data Supporting Long-Term Durability of Susvimo in Neovascular Age-Related Macular Degeneration

Andy Studna, Senior Editor
New results from the Phase III Portal extension study show that Susvimo maintained vision and disease control over five years in neovascular AMD, with 95% of patients requiring no supplemental treatment between six-month refill intervals.
ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials
August 5th 2025

ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials

Applied Clinical Trials Editorial Staff
In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials in the US, why experts warn it violates core ethical standards, and how these proposals could jeopardize both participant safety and future innovation.
© photon_photo - © photon_photo - stock.adobe.com
August 5th 2025

Clinical Trial Failure Isn’t an Inevitable Risk—It’s Insurable and Opening the Door to New Investors

Scott Foster Natalie Marquess, ARM, CIC, CRM
Clinical trial failure insurance is turning biotech’s most costly risk into a manageable asset, opening new pathways for funding and innovation.
Unifying Industry to Better Understand GCP Guidance
August 5th 2025

Unifying Industry to Better Understand GCP Guidance

Andy Studna, Senior Editor
In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Clears Alphamab’s Anti-HER2 Biparatopic Antibody-Drug Conjugate for Phase II Ovarian Cancer Trial
August 5th 2025

FDA Clears Alphamab’s Anti-HER2 Biparatopic Antibody-Drug Conjugate for Phase II Ovarian Cancer Trial

Don Tracy, Associate Editor
The FDA’s green light for a Phase II trial (JSKN003-202) of JSKN003 accelerates efforts to address platinum-resistant ovarian and related gynecologic cancers.
Image Credit: Adobe Stock Images/MUdaylah
August 5th 2025

Obicetrapib Shows Alzheimer’s Biomarker Reduction in Phase III BROADWAY Trial

Andy Studna, Senior Editor
In a pre-specified sub-study of the BROADWAY trial, obicetrapib 10 mg significantly reduced plasma p-tau217 levels in patients with ASCVD, including ApoE4 carriers, suggesting dual potential to lower LDL-C and impact Alzheimer’s disease progression.
© 2025 MJH Life Sciences

All rights reserved.